今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

一键报案、理赔进度可查！平安车险强强联手小鹏App，为车主提供更便捷的保险服务

上海 - 2024年6月5日 - 致力于为车主提供更便捷、更智能的出行体验的小鹏汽车今日宣布，携手平安车险，将平安车险的报案快撤功能上线小鹏App，为小鹏品牌保险车主提供一键报案、快速撤离事故现场的服务。

此次合作，标志着小鹏汽车与平安车险在汽车保险领域的深度融合，进一步提升了小鹏汽车的数字化服务能力，为车主打造更加安心、便捷的用车体验。

一键报案，快速撤离

对于符合条件的事故，小鹏车主可以通过小鹏App轻松实现一键报案。系统会自动收集事故信息，并快速调取车辆行驶数据、周边监控视频等证据，帮助车主完成报案流程。在保险公司核实事故信息后，车主即可快速撤离事故现场，避免影响交通秩序。

理赔进度实时可查

除了便捷的报案服务外，平安车险还为小鹏车主提供了理赔进度的实时查询服务。车主可以通过小鹏App随时查询理赔进度的最新进展，了解案件处理情况，避免因信息不对称造成焦急等待。

强强联手，共创未来

此次合作，是双方在数字保险领域的强强联手。小鹏汽车作为国内领先的新能源汽车品牌，拥有强大的用户基础和数据积累；平安车险则是国内领先的保险公司，拥有丰富的保险产品和理赔经验。双方优势互补，将为车主提供更加优质的保险服务。

关于小鹏汽车

小鹏汽车致力于为用户创造智能、美好的出行体验。公司于2015年成立，拥有核心技术研发、整车制造、销售服务、用户运营等全产业链布局。小鹏汽车先后推出了P7、P5、G9等多款智能电动汽车，产品以其出色的设计、智能的驾驶辅助系统和高品质的整车性能，赢得了用户的广泛认可。

关于平安车险

平安车险是中国平安保险（集团）股份有限公司旗下专业从事汽车保险业务的子公司，是中国最大的非寿险公司之一。平安车险拥有强大的综合实力，为车主提供全方位的车险产品和服务，包括车损险、第三者责任险、车上人员险、不计免赔险等。